For biotech and biopharma development teams
A pivotal study, a manufacturing change, a regulatory interaction, or a first European filing rarely affects just one part of a program. Decisions about dose, evidence, comparators, supply, and future access can become much harder to revisit later. VCLS (Voisin Consulting Life Sciences) helps development teams identify those dependencies and decide what needs attention before the next milestone.
Before pivotal development
Examine dose and regimen, early efficacy, safety, study design, model relevance, and manufacturing changes before those choices become expensive to revisit.
Explore pivotal readinessEvidence through approval and access
Consider how regulators, value assessors, clinicians, and patients may use the pivotal evidence, and where future comparator, outcomes, or supply questions have not yet been addressed.
Explore connected evidenceUS-to-Europe rare disease development
Identify questions around patient population, external controls, relevant treatment options, European regulatory advice, and the evidence needed for access.
Explore Europe planningA clear answer in one function can still create a difficult question for another. These six questions help teams see the dependencies before a high-cost decision is made.
Manufacturing
A Phase I/II process may be adequate for early clinical supply but unsuitable for expected commercial demand.
The earlier the future change and its comparability requirements are considered, the more options remain.
Clinical and nonclinical evidence
Target binding alone does not establish that a nonclinical model is suitable for the decision being made.
Understanding where the model differs from human biology can change the evidence program and the clinical monitoring strategy before definitive studies begin.
Regulatory and global development
Agreement with FDA on a specific development question is valuable.
It is not automatically agreement on the whole program, nor a substitute for considering what European authorities may ask.
Before pivotal development
Which choices will be difficult to revisit once the study starts? Our clinical, nonclinical, and CMC teams can help frame questions about dose, safety, early signals, design, process readiness, and comparability before those issues are inherited by a later team.
Topics
Evidence through approval and access
Regulatory approval and comparative value are related but distinct questions. A trial may support a positive benefit-risk assessment without providing every comparator, patient outcome, or resource-use measure needed later. The aim is to recognize the important downstream questions early enough to influence evidence planning.
Topics
US-to-Europe rare disease development
An FDA-aligned rare disease strategy can be well founded while still containing assumptions that have never been tested in Europe. Population definitions, treatment pathways, external comparisons, nonclinical evidence, and advice timing may need an independent European review.
Topics
No need to prepare a full briefing dossier for an initial inquiry. Please do not include confidential program data or patient-level information in the form.
Share a few details and we’ll direct your inquiry to the appropriate VCLS team.
VCLS will use these details to respond to your inquiry. Read our Privacy Policy.
VCLS brings regulatory, clinical, nonclinical, CMC, real-world evidence, market access, and lifecycle expertise to complex therapeutic development. The aim is to consider how today’s development choices affect the decisions that follow.
No. The questions are especially valuable before pivotal decisions, but companies at earlier stages can use them to identify which evidence and regulatory assumptions should be tested next.
VCLS supports global regulatory and development planning. An initial inquiry can help clarify the jurisdictions and decisions that need closer attention.
No. Start with the program stage and the specific development question. We can then determine what information is appropriate for a further discussion.
It is an initial scoping conversation. It does not replace a formal program-specific assessment or advice from the relevant authority.